Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 4/2012

01.04.2012 | Review Article

Biology and significance of circulating and disseminated tumour cells in colorectal cancer

verfasst von: Gunnar Steinert, Sebastian Schölch, Moritz Koch, Jürgen Weitz

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

More than 130 years ago, circulating tumour cells (CTCs) and disseminated tumour cells (DTCs) have been linked to metastasis. Since then, a myriad of studies attempted to characterise and elucidate the clinical impact of CTCs/DTCs, amongst others in colorectal cancer (CRC). Due to a flood of heterogeneous findings regarding CTCs/DTCs in CRC, this review aims to describe the known facts about CTC/DTC biology and clinical impact.

Methods

To identify the basic scientific literature regarding the biology and clinical impact of CTCs/DTCs in CRC, we reviewed the literature in the PubMed database. We focused on publications written in English and published until January 2012. As search terms, we used “colorectal cancer (CRC)”, “colon cancer (CC)”, “CTC”, “DTC”, “bone marrow (BM)”, “lymph node (LN)”, “peripheral blood (PB)”, “significance” and “prognosis”.

Results

CTC detection and quantification under standardised conditions is feasible. Several studies in large patient settings have revealed prognostic impact of CTCs in CRC. CRC-derived DTC detection and analysis in BM exhibits a more heterogeneous picture but also shows clinical value. Furthermore, the presence of DTCs in LN has a strong prognostic impact in CRC.

Conclusions

Clinical relevance and prognostic significance of CTCs/DTCs in CRC have been clearly demonstrated in many experimental studies. The major challenge in CTC/DTC research is now to harmonise the various identification and detection approaches and consequently to conduct large prospective multi-institutional trials to verify the use of CTCs/DTCs as a valid prognostic and predictive biomarker for clinical routine.
Literatur
1.
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456PubMed
2.
Wolfrum F et al (2005) Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 390(5):430–441PubMed
3.
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMed
4.
Thorsteinsson M, Jess P (2011) The clinical significance of circulating tumor cells in non-metastatic colorectal cancer—a review. Eur J Surg Oncol 37(6):459–465PubMed
5.
Weitz J et al (2005) Colorectal cancer. Lancet 365(9454):153–165PubMed
6.
Hess KR et al (2006) Metastatic patterns in adenocarcinoma. Cancer 106(7):1624–1633PubMed
7.
Ashworth, TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Medical Journal 14:146–7
8.
Zhan M, Zhao H, Han ZC (2004) Signalling mechanisms of anoikis. Histol Histopathol 19(3):973–983PubMed
9.
Sachdev D et al (2010) The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29(2):251–262PubMed
10.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458PubMed
11.
Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564PubMed
12.
Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMed
13.
Sun YF et al (2011) Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137(8):1151–1173PubMed
14.
Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14(6):818–829PubMed
15.
Morel AP et al (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3(8):e2888PubMed
16.
Sabbah M et al (2008) Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11(4–5):123–151PubMed
17.
Vincan E et al (2007) A human three-dimensional cell line model allows the study of dynamic and reversible epithelial-mesenchymal and mesenchymal-epithelial transition that underpins colorectal carcinogenesis. Cells Tissues Organs 185(1–3):20–28PubMed
18.
Loboda A et al (2011) EMT is the dominant program in human colon cancer. BMC Med Genomics 4:9PubMed
19.
Lecharpentier A et al (2011) Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105(9):1338–1341PubMed
20.
Hiratsuka S et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375PubMed
21.
Kang SY et al (2009) Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A 106(29):12115–12120PubMed
22.
Kaplan RN et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827PubMed
23.
Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6(6):449–458PubMed
24.
Weiss L (1990) Metastatic inefficiency. Adv Cancer Res 54:159–211PubMed
25.
Gout S, Tremblay PL, Huot J (2008) Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 25(4):335–344PubMed
26.
Camerer E et al (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104(2):397–401PubMed
27.
Nieswandt B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59(6):1295–1300PubMed
28.
Hou JM et al (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178(3):989–996PubMed
29.
Pawelek JM, Chakraborty AK (2008) The cancer cell–leukocyte fusion theory of metastasis. Adv Cancer Res 101:397–444PubMed
30.
Abdel-Ghany M et al (2001) The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 276(27):25438–25446PubMed
31.
Brown DM, Ruoslahti E (2004) Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5(4):365–374PubMed
32.
Wang H et al (2004) Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 164(6):935–941PubMed
33.
Kim MY et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315–1326PubMed
34.
Chang YS et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 97(26):14608–14613PubMed
35.
Brooks DE (1984) The biorheology of tumor cells. Biorheology 21(1–2):85–91PubMed
36.
Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340PubMed
37.
Smirnov DA et al (2005) Global gene expression profiling of circulating tumor cells. Cancer Res 65(12):4993–4997PubMed
38.
Solmi R et al (2006) Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer 6:250PubMed
39.
Zieglschmid V et al (2007) Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res 27(4A):1823–1832PubMed
40.
Lankiewicz S et al (2008) Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell Oncol 30(6):463–471PubMed
41.
Lankiewicz S et al (2008) Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2(4):349–355PubMed
42.
Findeisen P et al (2008) Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol 33(5):1001–1010PubMed
43.
Gazzaniga P et al (2010) Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med 14(8):2073–2077PubMed
44.
Wong SC et al (2011) Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer 104(6):1000–1006PubMed
45.
Xi L et al (2007) Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 53(7):1206–1215PubMed
46.
Riethdorf S, Wikman H, Pantel K (2008) Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123(9):1991–2006PubMed
47.
Klein CA et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689PubMed
48.
Stoecklein NH, Klein CA (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 126(3):589–598PubMed
49.
Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302–312PubMed
50.
Weber JC et al (2007) Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. Int J Cancer 120(3):524–532PubMed
51.
Conzelmann M, Linnemann U, Berger MR (2005) Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use? Int J Colorectal Dis 20(2):137–146PubMed
52.
Kraus MC, Linnemann U, Berger MR (2011) Disseminated colorectal tumor cells in organs prone to metastasis detected by new double enriched nested-PCR in comparison with recognized assays. Oncol Rep 25(5):1421–1429PubMed
53.
Tortola S et al (2001) Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 19(11):2837–2843PubMed
54.
Braun S et al (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18(1):80–86PubMed
55.
Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. APMIS 116(7–8):754–770PubMed
56.
Sosa MS et al (2011) ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 17(18):5850–5857PubMed
57.
Alencar H et al (2005) A novel mouse model for segmental orthotopic colon cancer. Int J Cancer 117(3):335–339PubMed
58.
Bhullar JS et al (2011) A novel nonoperative orthotopic colorectal cancer murine model using electrocoagulation. J Am Coll Surg 213(1):54–60, discussion 60–1PubMed
59.
Bresalier RS et al (1987) An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 47(5):1398–1406PubMed
60.
Donigan M et al (2010) A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc 24(3):642–647PubMed
61.
Eliane JP et al (2008) Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res 68(14):5529–5532PubMed
62.
Fu XY et al (1991) Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A 88(20):9345–9349PubMed
63.
Galanzha EI et al (2009) In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69(20):7926–7934PubMed
64.
Kolostova K et al (2011) Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. Anticancer Res 31(5):1535–1539PubMed
65.
Lupu CM et al (2006) An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 10(5):635–645PubMed
66.
Zigmond E et al (2011) Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. PLoS One 6(12):e28858PubMed
67.
Peach G et al (2010) Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 102(9):1327–1334PubMed
68.
Rahbari NN et al (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138(5):1714–1726PubMed
69.
Weitz J et al (1998) Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 4(2):343–348PubMed
70.
Bessa X et al (2001) Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 120(5):1084–1092PubMed
71.
Bessa X et al (2003) Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg 237(3):368–375PubMed
72.
Bosch B et al (2003) Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 90(7):882–888PubMed
73.
Koch M et al (2005) Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 241(2):199–205PubMed
74.
Allen-Mersh TG et al (2007) Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 94(1):96–105PubMed
75.
Koyanagi K et al (2008) Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res 14(22):7391–7396PubMed
76.
Uen YH et al (2008) Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I–III colorectal cancer after curative resection. Ann Surg Oncol 15(8):2120–2128PubMed
77.
Allard WJ et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904PubMed
78.
Negin BP, Cohen SJ (2010) Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 11(1–2):1–13PubMed
79.
Cohen SJ et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221PubMed
80.
Cohen SJ et al (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20(7):1223–1229PubMed
81.
Tol J et al (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19(4):734–738PubMed
82.
Wong SC et al (2009) Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 15(3):1005–1012PubMed
83.
Lindemann F et al (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340(8821):685–689PubMed
84.
Pantel K et al (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347(9002):649–653PubMed
85.
Leinung S et al (2000) Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg 385(5):337–343PubMed
86.
Broll R et al (1996) Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma. Langenbecks Arch Chir 381(1):51–58PubMed
87.
Cohen AM et al (1998) In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases. Dis Colon Rectum 41(9):1112–1115PubMed
88.
Juhl H et al (1994) Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 57(3):330–335PubMed
89.
Schott A et al (1998) Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227(3):372–379PubMed
90.
Flatmark K et al (2002) Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 8(2):444–449PubMed
91.
Pantel K et al (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3(3):165–173PubMed
92.
Schoppmeyer K et al (2006) Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases. Oncol Rep 15(2):449–454PubMed
93.
O’Sullivan GC et al (1997) Micrometastases: marker of metastatic potential or evidence of residual disease? Gut 40(4):512–515PubMed
94.
Leinung S et al (2000) Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res 9(6):905–911PubMed
95.
Vlems FA et al (2003) Detection of disseminated tumour cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. Br J Surg 90(8):989–995PubMed
96.
Soeth E et al (1996) The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer 69(4):278–282PubMed
97.
Soeth E et al (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 57(15):3106–3110PubMed
98.
Gerhard M et al (1994) Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12(4):725–729PubMed
99.
Conzelmann M et al (2003) Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Int J Cancer 107(4):617–628PubMed
100.
Ausch C et al (2009) Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg 13(11):2020–2026PubMed
101.
Buergy D et al (2009) Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer 115(20):4667–4678PubMed
102.
Vogelaar FJ et al (2010) Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study. BMC Cancer 10:153PubMed
103.
Buxhofer-Ausch V et al (2010) Spontaneous changes in tumour cell dissemination to bone marrow in colorectal cancer. Colorectal Dis 12(8):776–782PubMed
104.
Valladares-Ayerbes M et al (2011) Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int J Oncol 39(5):1253–1264PubMed
105.
Greenson JK et al (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73(3):563–569PubMed
106.
Nakanishi Y et al (1999) Clinical implications of lymph node micrometastases in patients with colorectal cancers. A case control study. Oncology 57(4):276–280PubMed
107.
Oberg A et al (1998) Are lymph node micrometastases of any clinical significance in Dukes stages A and B colorectal cancer? Dis Colon Rectum 41(10):1244–1249PubMed
108.
Weitz J et al (1999) Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res 5(7):1830–1836PubMed
109.
Rosenberg R et al (2004) Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer. Int J Colorectal Dis 19(5):430–437PubMed
110.
Conzelmann M, Linnemann U, Berger MR (2004) K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int J Oncol 24(6):1537–1544PubMed
111.
Rahbari NN, et al. (2012) Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. doi:10.​1200/​JCO.​2011.​36.​9504
Metadaten
Titel
Biology and significance of circulating and disseminated tumour cells in colorectal cancer
verfasst von
Gunnar Steinert
Sebastian Schölch
Moritz Koch
Jürgen Weitz
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 4/2012
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-012-0917-9

Weitere Artikel der Ausgabe 4/2012

Langenbeck's Archives of Surgery 4/2012 Zur Ausgabe

Review Article

Chemoprevention of pancreatic cancer—one step closer

Review Article

Immune mediators of postoperative ileus

Review Article

Immune responses triggering colitis and colitis-associated carcinoma

Abstracts

129th Congress of the German Society for Surgery

Review Article

A critical appraisal of the hemodynamic signal driving liver regeneration

Review Article

The Study Centre of the German Surgical Society: current trials and results

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.